N4 PHARMA PLC

Management Reports • Jun 30, 2025

National Storage Mechanism | Additional information

RNS Number : 0274P

N4 Pharma PLC

30 June 2025

30 June 2025

N4 Pharma plc

("N4 Pharma" or the "Company")

Result of AGM

N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed. 

Resolution	For	For%	Against	Against%	Total	Witheld votes*
Ordinary Resolution 1 To receive the annual report and audited accounts for the year ended 31 December 2024	30,108,642	99.98%	7,304	0.02%	30,115,946	300,591
Ordinary Resolution 2 To re-elect Luke Cairns as a Director of the Company	30,061,328	99.98%	7,304	0.02%	30,068,632	98,809
Ordinary Resolution 3 To re-elect Chris Britten as a Director of the Company	30,061,328	99.98%	7,304	0.02%	30,068,632	98,809
Ordinary Resolution 4 To elect Michael Palfreyman as a Director of the Company	30,085,134	99.97%	8,504	0.03%	30,093,638	80,791
Ordinary Resolution 5 To elect Alastair Smith as a Director of the Company	30,078,746	99.97%	8,504	0.03%	30,087,250	80,791
Ordinary Resolution 6 To appoint Gravita Audit II Limited as the Companyʼs auditor and to authorise the Directors to determine their remuneration	30,085,034	99.98%	7,304	0.02%	30,092,338	93,799
Ordinary Resolution 7 To authorise the Directors to allot shares	30,060,137	99.98%	7,304	0.02%	30,067,441	92,193
Special Resolution 8 To disapply pre-emption rights	29,942,019	99.97%	10,004	0.03%	29,952,023	92,393

*Please note a vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

- Ends -

For more information please contact:

N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director Submit your questions directly to the management team via the N4 Pharma Investor Hub	Via N4 Pharma Investor Hub: investors.n4pharma.com https://investors.n4pharma.com/link/5PmqMP
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)	Tel: +44 (0)20 3470 0470
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope	Tel: +44 (0)20 3657 0050
Northstar Communications Limited Investor Relations Sarah Hollins	Tel: +44 (0)113 730 3896

About N4 Pharma

N4 Pharma is a pre-clinical biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases .

RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.

N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.

N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for IBD which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.

For further information on the Company visit www.n4pharma.com or sign up at https://investors.n4pharma.com/auth/signup .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGBXGDLSBXDGUG